SwRI and UTSA will work together to combat the growing threat antimicrobial resistance poses to global health by developing a proof-of-concept platform to potentially create a whole library of new ...
The US Food and Drug Administration (FDA) has approved a 420 mg dosage strength of Hercessi (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab). Hercessi, a HER2/neu receptor antagonist, is ...
Talazoparib is under clinical development by Pfizer and currently in Phase I for Bladder Cancer. According to GlobalData, Phase I drugs for Bladder Cancer have a 75% phase transition success rate ...
About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers ...